XML 32 R11.htm IDEA: XBRL DOCUMENT v3.6.0.2
Other Comprehensive Income (Loss)
12 Months Ended
Dec. 31, 2016
Stockholders' Equity Note [Abstract]  
Other Comprehensive Income (Loss) [Text Block]

5. Other Comprehensive Income (Loss)

 

The accumulated balances related to each component of other comprehensive income (loss) were as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

    

Foreign

    

 

 

    

Accumulated

 

 

 

Currency

 

Unrealized Net

 

Other

 

 

 

Translation

 

Gains (Losses)

 

Comprehensive

 

 

 

Gains (Losses)

 

on Securities

 

Gains (Losses)

 

Balance at December 31, 2013

 

$

(11,816)

 

$

68,507

 

$

56,691

 

Unrealized loss

 

 

(38,776)

 

 

(165,285)

 

 

(204,061)

 

Net amount reclassified to net income

 

 

 

 

3,442

 

 

3,442

 

Other comprehensive loss

 

 

(38,776)

 

 

(161,843)

 

 

(200,619)

 

Balance at December 31, 2014

 

$

(50,592)

 

$

(93,336)

 

$

(143,928)

 

Unrealized gain (loss)

 

 

(1,352)

 

 

18,841

 

 

17,489

 

Net amount reclassified to net loss

 

 

51,944

 

 

(4,904)

 

 

47,040

 

Other comprehensive income

 

 

50,592

 

 

13,937

 

 

64,529

 

Balance at December 31, 2015

 

$

 —

 

$

(79,399)

 

$

(79,399)

 

Unrealized gain

 

 

 —

 

 

36,908

 

 

36,908

 

Net amount reclassified to net loss

 

 

 —

 

 

1,295

 

 

1,295

 

Other comprehensive income

 

 

 —

 

 

38,203

 

 

38,203

 

Balance at December 31, 2016

 

$

 —

 

$

(41,196)

 

$

(41,196)

 

 

The assets and liabilities of foreign operations were translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally did not affect cash flows, which resulted in translation adjustments made in stockholders’ equity rather than to net income (loss). The accumulated balance of translation adjustments for Endocyte Europe B.V. were reclassified out of accumulated other comprehensive income (loss) and recognized as foreign currency translation losses reported in other income (expense) as the Company determined that the liquidation of Endocyte Europe B.V. was substantially complete as of December 31, 2015. There were no transactions from foreign operations in the year ended December 31, 2016.

 

Reclassifications Out of Accumulated Other Comprehensive Income (Loss)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amount Reclassified from Accumulated

 

 

 

 

 

Other Comprehensive Income (Loss)

 

Affected Line Item in the

 

 

 

Year Ended

 

Year Ended

 

Year Ended

 

Consolidated

 

Details about Accumulated Other

 

December 31, 

 

December 31, 

 

December 31, 

 

Statements of Operations and

 

Comprehensive Income (Loss) Components

 

2014

 

2015

 

2016

 

Comprehensive Income (Loss)

 

Unrealized Net Gains (Losses) on Securities

    

$

3,442

    

$

(4,904)

    

$

1,295

    

Other income (expense)

 

Foreign Currency Translation Losses

 

 

 

 

51,944

 

 

 —

 

Other income (expense)

 

Total Reclassifications for the Period

 

$

3,442

 

$

47,040

 

$

1,295